Assessment of club drug use in a treatment-seeking sample of individuals with marijuana dependence.
Club drug use is becoming increasingly popular in the United States and has been associated with chronic psychiatric symptoms and neuropsychological abnormalities. Patterns of club drug use and characteristics of club drug users are not homogeneous. Thus, treatment-seeking marijuana-dependent individuals may have a differential pattern of club drug use. Baseline assessments collected from 55 individuals participating in a pharmacological treatment study for marijuana dependence were examined. Individuals completed a 16-item self-report questionnaire assessing club drugs used, frequency and patterns of use, problems associated with use, and reasons for use. Subjects were primarily male (87.3%) and Caucasian (81.8%), with a mean age of 32.1 (+/-9.1 years). As expected, a large number of individuals had used ecstasy (75%). However, LSD and methamphetamine use was also reported by many users (82.5% and 47.5% respectively), with many individuals reporting the use of more than one club drug. Notably, 31.6% of individuals reported tolerance to club drugs. These results emphasize the significant co-occurrence of club drug use in marijuana-dependent individuals. This appears to be the first study to report on club drug use in treatment-seeking marijuana-dependent individuals. Clinical implications and directions for future research are discussed.
Verduin
Marcia L
ML
Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, USA. mverduin@mail.ucf.edu
Payne
Rebecca A
RA
McRae
Aimee L
AL
Back
Sudie E
SE
Simpson
Stacey A
SA
Sarang
Rajesh Y
RY
Brady
Kathleen T
KT
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D017668:Age of Onset; D015897:Comorbidity; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000453:epidemiology / Q000523:psychology / Q000628:therapy*; D008694:Methamphetamine / Q000009:adverse effects; D009042:Motivation; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects; D010342:Patient Acceptance of Health Care / Q000523:psychology*; D010555:Personality Inventory; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D012919:Social Behavior; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology; D011795:Surveys and Questionnaires
D008694:Methamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine